The development of antitumor therapy based on the suppression of NF-κB activity is justified by convincing experimental data that identify NF-κB as a key promoter of tumorigenesis; however, care should be taken when considering anti-NF-κB activity as a general therapeutic strategy in the treatment of cancer because data also show that NF-κB activity increases tumor cell sensitivity to apoptosis and senescence. The gene discussed is NFKB1; the disease is cancer.